Target intelligence / Profile preview

Copper ion binding/sequestration

Molecular classification
Metalloprotein, Chaperone, Enzyme (certain copper-binding proteins), Transporter (certain copper-binding proteins), Other (for proteins outside classical families)
01

Overview

Copper ion binding/sequestration denotes the ability of various proteins—including prion protein (PrP), copper chaperones (e.g., CopZ), metalloproteins (e.g., MbnP, MopE*, CorA)—to specifically bind and control copper ions through conserved motifs such as histidine- and methionine-rich sequences[1][2][5]. These proteins regulate copper availability for cellular processes, protect against oxidative damage, and are critical for enzymatic activities and structural integrity[6]. Dysregulation of copper binding is linked to neurodegenerative diseases, infection susceptibility, and metabolic disorders[3][6][1]. The term refers to a function; to study a specific therapeutic target, an individual copper-binding protein or its gene should be identified.

Other names
copper-binding proteincopper chaperonecopper transporterCBPCopZprion protein (PrP)
02

Mechanism of action

Chelation and removal of copper ions\nModulation of copper-binding affinity\nInhibition or stabilization of copper-binding proteins\nRestoration or suppression of copper-dependent enzymatic activity

03

Biological functions

Metal ion homeostasisRedox regulationEnzymatic catalysisNeuroprotectionCopper transportCopper detoxificationStructural stabilization
04

Disease associations

Neurodegenerative disease (e.g., prion disorders, Alzheimer's disease)Infection (certain pathogens use copper-binding proteins for virulence)Cancer (dysregulated copper metabolism implicated in some tumors)InflammationOther (e.g., Wilson's disease, Menkes disease, copper toxicity)
05

Safety considerations

Disruption of systemic copper homeostasis (risk of copper deficiency or toxicity)Off-target effects for broadly acting chelatorsNeurotoxicity risk if copper-binding proteins involved in CNS protection are inhibited
06

Interacting drugs

Chelators (penicillamine, trientine)

3 more in the full profile.

07

Biomarkers

Serum copper levelsCeruloplasmin (plasma copper-binding protein)Prion protein levels (in prion diseases)CBP expression (research context)

Beyond the preview

Go deeper on Copper ion binding/sequestration.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Copper ion binding/sequestration.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call